Ado-trastuzumab emtansine-associated telangiectasias in metastatic breast cancer: A case series Journal Article
| Authors: | Sibaud, V.; Niec, R. E.; Schindler, K.; Busam, K. J.; Roché, H.; Modi, S.; Delord, J. P.; Lacouture, M. E. |
| Article Title: | Ado-trastuzumab emtansine-associated telangiectasias in metastatic breast cancer: A case series |
| Abstract: | Treatment of HER2-positive metastatic breast cancer with ado-trastuzumab emtansine (T-DM1), a novel antibody-drug conjugate, has resulted in both improved progression-free and overall survival. Recognition and treatment of diverse adverse events related to T-DM1 is critical for safety and tolerability. The most frequent adverse events with T-DM1 include fatigue, diarrhea, anemia, elevated transaminases, and mild-to-moderate hemorrhagic events, which are thought to be related to induced thrombocytopenia. Here, we present five case series of cutaneous and mucosal telangiectasias, definitely related to T-DM1. The development of telangiectasias represents a newly recognized adverse effect of T-DM1. We provide description and timing of the telangiectasias and review the mechanisms that may explain the formation of these vascular lesions in association with T-DM1. Further, we describe associated bleeding events and propose that induced telangiectasias could represent an additional cause of T-DM1-associated hemorrhage. © 2014 Springer Science+Business Media. |
| Keywords: | breast cancer; thrombocytopenia; telangiectasia; hemorrhage; t-dm1; ado-trastuzumab emtansine; spider nevus |
| Journal Title: | Breast Cancer Research and Treatment |
| Volume: | 146 |
| Issue: | 2 |
| ISSN: | 0167-6806 |
| Publisher: | Springer |
| Date Published: | 2014-07-01 |
| Start Page: | 451 |
| End Page: | 456 |
| Language: | English |
| DOI: | 10.1007/s10549-014-3001-z |
| PROVIDER: | scopus |
| PUBMED: | 24929675 |
| DOI/URL: | |
| Notes: | Export Date: 1 August 2014 -- CODEN: BCTRD -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work